Lilly psoriasis drug hits Phase-III endpoint

Eli Lilly and Incyte announced Tuesday that its investigational moderate to severe psoriasis drug baricitinib met its primary endpoint, in a Phase-III trial. The JAK inhibitor is meant for patients who have failed one or more TNF inhibitors, like J&J's Remicade and Simponi, Amgen's Enbrel, AbbVie's Humira or UCB's Cimzia. Details from the triall will be presented at meetings in 2015 as baricitinib's safety and efficacy is currently being evaluated in another Phase-III trial.  Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib in December 2009.